09.21.15
Medford, Mass.-based Seventh Sense BioSystems Inc., which makes blood collection and diagnostic platforms, is expanding its manufacturing operations and relocating its home office.
“This new facility provides Seventh Sense with a unique opportunity to house all of its functions under one roof to support a successful product launch in 2016,” said Howard Weisman, president and CEO of Seventh Sense. “Demand for our proprietary painless blood collection device continues to grow and this move to our new manufacturing and office space will support our continued growth and expansion.”
Seventh Sense BioSystems’ new device is the TAP, a proprietary platform that draws capillary blood in a painless, one-step process without having to access a vein. It can be used across and integrated with a broad spectrum of diagnostic applications, the company reports. The TAP system penetrates the uppermost layers of skin through the use of micro-needles, collects capillary blood using a novel microfluidic extraction process, and stabilizes the blood with anticoagulant if required. The device has a visual indicator to confirm that collection is complete. The TAP platform is designed for fully automated, high throughput manufacturing.
“This new facility provides Seventh Sense with a unique opportunity to house all of its functions under one roof to support a successful product launch in 2016,” said Howard Weisman, president and CEO of Seventh Sense. “Demand for our proprietary painless blood collection device continues to grow and this move to our new manufacturing and office space will support our continued growth and expansion.”
Seventh Sense BioSystems’ new device is the TAP, a proprietary platform that draws capillary blood in a painless, one-step process without having to access a vein. It can be used across and integrated with a broad spectrum of diagnostic applications, the company reports. The TAP system penetrates the uppermost layers of skin through the use of micro-needles, collects capillary blood using a novel microfluidic extraction process, and stabilizes the blood with anticoagulant if required. The device has a visual indicator to confirm that collection is complete. The TAP platform is designed for fully automated, high throughput manufacturing.